With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is
to maintain the currently successful cure rate and reduce treatment related side effects and
long term toxicity. The main purpose of this study is to estimate the event free survival of
patients treated with risk-adapted therapy compared to historical controls.